APA (7th ed.) Citation

Prince, H. M., Schenkel, B., & Mileshkin, L. (2007). Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: A study of bortezomib and thalidomide. Leukemia (08876924), 21(4), 818. https://doi.org/10.1038/sj.leu.2404573

Chicago Style (17th ed.) Citation

Prince, H. M., B. Schenkel, and L. Mileshkin. "Assessing Response Rates in Clinical Trials of Treatment for Relapsed or Refractory Multiple Myeloma: A Study of Bortezomib and Thalidomide." Leukemia (08876924) 21, no. 4 (2007): 818. https://doi.org/10.1038/sj.leu.2404573.

MLA (9th ed.) Citation

Prince, H. M., et al. "Assessing Response Rates in Clinical Trials of Treatment for Relapsed or Refractory Multiple Myeloma: A Study of Bortezomib and Thalidomide." Leukemia (08876924), vol. 21, no. 4, 2007, p. 818, https://doi.org/10.1038/sj.leu.2404573.